Patents by Inventor Qiao Zhou
Qiao Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11136554Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: GrantFiled: March 4, 2019Date of Patent: October 5, 2021Assignee: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Qiao Zhou
-
Publication number: 20190376040Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: ApplicationFiled: March 4, 2019Publication date: December 12, 2019Inventors: Douglas A. Melton, Qiao Zhou
-
Patent number: 10221393Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: GrantFiled: June 19, 2017Date of Patent: March 5, 2019Assignee: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Qiao Zhou
-
Publication number: 20170355962Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: ApplicationFiled: June 19, 2017Publication date: December 14, 2017Inventors: Douglas A. Melton, Qiao Zhou
-
Patent number: 9683215Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: GrantFiled: August 24, 2009Date of Patent: June 20, 2017Assignee: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Qiao Zhou
-
Patent number: 9152459Abstract: In some implementations, a processor is configured to receive a current pending packet number representing a number of packets of data that currently remain to be transferred between two devices, determine whether to adjust a priority of a thread based on the current pending packet number, a previous pending packet number, and a priority pending packet number, and adjust or maintain the priority of the thread based on determining whether to adjust the priority of the thread. The thread is to be executed by the processor to perform a transfer of the packets of data between the two devices, the previous pending packet number represents a number of packets of data that previously remained to be transferred between the two devices, and the priority pending packet number corresponds to the current priority of the thread.Type: GrantFiled: April 23, 2013Date of Patent: October 6, 2015Assignee: Marvell World Trade Ltd.Inventors: Qiao Zhou, Xueming Zhao
-
Publication number: 20130283285Abstract: In some implementations, a processor is configured to receive a current pending packet number representing a number of packets of data that currently remain to be transferred between two devices, determine whether to adjust a priority of a thread based on the current pending packet number, a previous pending packet number, and a priority pending packet number, and adjust or maintain the priority of the thread based on determining whether to adjust the priority of the thread. The thread is to be executed by the processor to perform a transfer of the packets of data between the two devices, the previous pending packet number represents a number of packets of data that previously remained to be transferred between the two devices, and the priority pending packet number corresponds to the current priority of the thread.Type: ApplicationFiled: April 23, 2013Publication date: October 24, 2013Applicant: Marvell World Trade Ltd.Inventors: Qiao Zhou, Xueming Zhao
-
Publication number: 20110280842Abstract: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic ?-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic ?-cell.Type: ApplicationFiled: August 24, 2009Publication date: November 17, 2011Applicant: PRESIDENTS AND FELLOWS OF HARVARD COLLEGEInventors: Douglas A. Melton, Qiao Zhou
-
Patent number: 7732206Abstract: The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of OLPs and oligodendrocytes thus obtained for drug screening.Type: GrantFiled: April 4, 2006Date of Patent: June 8, 2010Assignee: California Institute of TechnologyInventors: David J. Anderson, Qiao Zhou
-
Publication number: 20070025975Abstract: The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of OLPs and oligodendrocytes thus obtained for drug screening.Type: ApplicationFiled: April 4, 2006Publication date: February 1, 2007Applicant: California Institute of TechnologyInventors: David Anderson, Qiao Zhou